2011 ANNUAL REPORT

FOUNDATION

MYELOMA

INTERNATIONAL





Improving Lives • Finding the Cure

Improving Lives • *Finding the Cure*

INTERNATIONAL MYELOMA FOUNDATION



Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.



2011 ANNUAL REPORT

TABLE OF CONTENTS

Letter from the Chairman	2
Update from the President	3
Research	4
Education	10
Support	13
Advocacy	15
Development	17
Financial Statements	21
Honor Roll	24





IMF Board of Directors

Brian G.M. Durie, MD Chairman of the Board Los Angeles, CA Mario Boccadoro, MD Professor, Cattedra Di Ematologia Torino, Italy Loraine Alterman Boyle

Journalist New York, NY **Mark S. Di Cicilia** Account Manager, Epicor Software Corporation

Orange, CA Donna Feig Vice President, Foreign Parts Distributors Miami Beach, FL

Michael S. Katz, MBA Senior Vice President, Booz & Company Bayside, NY

Benson Klein, JD Principal Member, Ward & Klein Bethesda, MD

Andrew J. Kuzneski III Principal, Kuzneski Financial Group President, Greyhawk Capital Indiana. PA

Robert A. Kyle, MD Professor of Medicine and Laboratory Medicine, Mayo Clinic

Rochester, MN Heinz Ludwig, MD Director of Department of Medicine I, Wilhelminenspital der Stadt Wien

Vienna, Austria Edith P. Mitchell, MD Clinical Professor of Medicine, Thomas Jefferson University Brigadier General, National Guard Philadelphia, PA

Charles Newman, MS Founder, CEO & President, ReCellular, Inc. Principal, Newman Computer Group Ann Arbor, MI

Susie Novis President, International Myeloma Foundation Los Angeles, CA John O'Dwyer

Retired Businessman Plano, TX **S. Vincent Rajkumar, MD** Professor of Medicine, Mayo Clinic Rochester, MN

Matthew Robinson, MBA Vice President, Sales and Business Development Warner Bros. International Television

Los Angeles, CA E. Michael D. Scott, CPA, JD Proprietor & Executive Vice President, Vox Media Newtown, PA Igor Sill Co-Founder & Managing Director,

Geneva Venture Partners Founder & Chairman, Geneva Group International San Francisco, CA

Allan Weinstein, PhD Director, St. Francis Medical Technologies, Inc. Phoenix, AZ

Amy Weiss Executive Vice President, Business Affairs Brillstein Entertainment Partners Beverly Hills, CA

Brian G.M. Durie, MD, Chairman

Medical Director, AMyC Myeloma Consortium Specialist in Multiple Myeloma and Related Disorders Cedars-Sinai Outpatient Cancer Center at the Oschin Comprehensive Cancer Institute

Dear Supporters of the International Myeloma Foundation,

We have worked together for 20 years to help myeloma patients, their caregivers, and loved ones around the world. This year, our commitment to this mission proved as fruitful as ever. The work over the 2010-2011 fiscal year has strengthened patient care and treatment, bringing us closer to calling this disease "treatable."

In March 2011, the IMF launched the Asian Myeloma Network to support physician and patient education throughout Asia. Multiple myeloma is increasing in Asia, with an incidence that is approaching that of western countries, yet with a much larger population base. Launching the network and the China Myeloma Working Group in August 2011 represents a great leap toward increasing a research base and strengthening access of myeloma patient and caregiver support.

In June 2011, the IMF held its annual International Myeloma Working Group Summit in London. This summit was yet another opportunity to bring together leading researchers in the field of myeloma, to establish recommendations for management of the disease, and guide the direction of future research. You will find in this report further detail on the incredible research-driven publications produced throughout 2011 by the IMWG; publications which work to inform patients and caregivers of therapeutic advances and treatment management.

This year, we launched the Search for a Cure program, with the intent to seek and fund promising myeloma research. We funded incredible research through our 2011 grants and we collaborated with key researchers to communicate important findings.

As one of the Foundation's four main pillars, the Education division created a new tool to inform patients and their families about diagnosis and treatment information entitled "10 Steps to Better Care™." This is an interactive online, downloadable resource for patients and caregivers.

We are in the midst of an important era for the myeloma community; we are seeing more and more patient outcome improvements with novel drug agents, tailored therapies, and increased access to care and support. The IMF will continue to build upon its platform of research to inform more effective treatment regimens and will continue to support all who are affected by this disease.

I would like to thank all of our supporters and partners for enabling our mission to grow stronger and improving the care and treatment of myeloma.

Sincerely yours,

an Dur u

Brian G.M. Durie, MD Chairman, IMF Board of Directors

Susie Novis, President International Myeloma Foundation

Dear Friends, Supporters, and Members,

The International Myeloma Foundation celebrated its 20th anniversary during the 2010-2011 fiscal year. It turned out to be our biggest year ever with more than \$9.2 million received in support of our outstanding programs and services! As I look through the pages of this Annual Report, I am both humbled by and grateful for the opportunity to improve the lives of myeloma patients and family members, and to partner with the medical community. The IMF experienced a year of truly remarkable accomplishments through its Advocacy, Support, Education and Research programs.

In the area of Advocacy, IMF members worked tirelessly to provide oral testimony in state governments, which led to the successful passing of drug parity laws in New York, Mexico, and Texas. Through our partnership with other cancer advocacy organizations, we supported the re-introduction of the Cancer Coverage Parity Act of 2011 on the federal level, which has the potential to impact tens of thousands of lives.

The IMF Support Groups program grew steadily over the year; 150 groups in the United States, Canada, and Europe are now active. The volunteers that serve as support group leaders are the heroes of the IMF, helping people in the community on a daily basis.

Furthering Education, the IMF sponsored four incredibly strong Patient & Family Seminars featuring important discussions around new drug effectiveness, and eleven Regional Community Workshops; four of which had over 100 people in attendance. Last February in Boca Raton, a spontaneous – and highly unusual – wave of generosity initiated by IMF member Bob Feltzin resulted in donations totaling \$40,000 to the IMF research fund. I am very proud to have been able to establish a grant in his honor and memory.

In the area of Research, we experienced tremendous successes. We established the Asian Myeloma Network to extend the breadth of international myeloma education and research. We also announced research projects funded through this year's Brian D. Novis Grants; projects that will bring us closer to more effective care and treatment of myeloma.

As you read through these pages, consider the many different ways the IMF, through generous donor support, touches the lives of myeloma patients and caregivers who come to rely on its programs. The IMF has been in the business of improving lives and finding a cure for 20 years. With your support, we will continue making outstanding progress.

Warmly,

Susie Novis

Susie Novis President



IMF Staff

Susie Novis President Jennifer Scarne Chief Financial Officer Daniel Navid Senior Global Analyst Diane Moran Senior Vice President, Strategic Planning Heather Cooper Ortner Vice President, Development Lisa Paik Vice President, Clinical Education & Research Initiatives

Betty Arevalo

Database & Inventory Control Arin Assero Director of Advocacy Suzanne Battaglia Director of Member Events **Debbie Birns** Hotline Coordinato **Joanie Borbely Regional Director, Support Groups** Gregor Brozeit **European Programs** Meghan Buzby Grassroots Liaison **Kelly Cox** Regional Director, Support Groups Regional Community Workshops Janice Estrada Auction and Development Associate **Paul Hewitt** Hotline Coordinator Spencer Howard Meeting & Event Services Marya Kazakova Publications Editor **Missy Klepetar** Hotline Coordinator **Phil Lange** Accountan **Andrew Lebkuecher Regional Director, Support Groups** Kemo Lee Specialty Member Services Coordinator **Randi Lovett** Director of Annual Giving & Social Media **Danielle Loi** Assistant to Development & Medical Affairs **Aimee Martin** Advocacy Grassroots Liaison Jim Needham Publication Design Selma Plascencia Data Specialist, Office Manager **Chelsea Proctor Executive Assistant Abbie Rich** Webmaster **Thomas Shin IT Systems Admin Robin Tuohy Director of Support Groups** Judy Webb Hotline Coordinator



Ola Landgren, MD, PhD The National Cancer Institute Washington, DC

Dr. Landgren's work in cancer research began at the Karolinska Institute in Sweden in the mid-1990s. His early study began in the area of Hodgkin's Lymphoma and later his passion turned to the field of myeloma. Dr. Landgren's focus area in this field of research is around early myeloma biology and interventions, molecular imaging and profiling, drug development, correlative analyses, and populations-based studies.

In 2005, Dr. Landgren was introduced to the work of the IMF and joined the IMWG in 2010. His work on the advisory committee has been instrumental in the growth of the group's breadth of research. Currently, he is leading an important IMWG study on second tumors after myeloma diagnosis.

"Our work on the IMWG has allowed researchers who are working in this field to help patients increase collaboration with one another, to test hypotheses in other data sets, and to address and discuss important issues around our research."

Dr. Landgren hopes to continue to working with the IMWG to publish consensus statements and to inform myeloma patients, caregivers, and lifesaving drug manufacturers. "I would hope that our group continues to identify and address important, outstanding questions and that we also continue to foster relationships to stimulate young researchers to build their careers in the field of myeloma."

The IMF thanks Dr. Ola Landgren for his invaluable contribution to the mission of the IMWG.

RESEARCH

The International Myeloma Foundation is a leader of innovative, globally collaborative myeloma research that aims to improve the quality of life of those living with myeloma. The IMF is at the forefront of research and knowledge around "tailored treatment," where new and combined myeloma therapies aim to address the precise needs of each myeloma patient. Tailoring myeloma treatment will lead to an era where myeloma will be managed as a chronic disease rather than a terminal diagnosis.

International Myeloma Working Group

The IMF's International Myeloma Working Group (IMWG) consists of 159 leading myeloma researchers from around the world. They collaborate on a broad range of myeloma research projects. With a goal to improve myeloma treatment options and diagnostic systems, their work focuses on protocols to provide a more



durable remission for myeloma patients while improving quality of life, addressing the needs of both myeloma patients and the physicians who treat them.

In June 2011, the second annual IMF IMWG Summit was held in London, England, with a mission to identify, support, and implement

the most promising research to prevent onset of active disease, improve treatment, and find a cure for myeloma. This summit brought together 71 myeloma experts from 25 countries, representing 55 institutions, and led to discussions about the key issues surrounding myeloma, including the diagnosis and management of high-risk smoldering myeloma, induction therapy, maintenance versus consolidation therapy, the role of early transplantation, the integration of new and existing drugs, and risk stratification. Recommendations for publications and research were produced, which will inform future research projects and clinical trials.

IMWG PUBLICATIONS

Long-term IMWG research collaboration led to four publications during the October 2010–September 2011 reporting period:

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenterinternational myeloma working group study

Kumar S, Lee J, Lahuerta J, et al. *Leukemia*, July 2011; doi: 10. 1038/leu.2011.196. Epub ahead of print.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

Cavo M, Rajkumar SV, Palumbo A, et al. *Blood*, June 2011; 117(23): 6063-73. Epub March 29, 2011.



RESEARCH

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation (allo-SCT) for multiple myeloma

Lokhorst H, Einsele H, Vesole D, et al. *Journal of Clinical Oncology*, October 2010; 10;28(29): 4521-30. Epub August 9, 2010.

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

Terpos E, Dimopoulos M, Sezer O, et al. Leukemia, 2010; 24: 1700–1712.

Full text versions of IMWG publications and presentations may be accessed here: http://imwgpubs.myeloma.org

Asian Myeloma Network



On March 17, 2011, in Singapore the IMF launched the Asian Myeloma Network (AMN), which is composed of myeloma experts from China, Hong Kong, Taiwan, Japan, Rep. of Korea, Singapore, and Thailand. This network was initiated to spearhead physician education about myeloma and patient care and support throughout Asia. Multiple myeloma is a growing health problem in Asia, with an

incidence that is approaching that of Western countries, however with a much larger population base.

One aim of this network is the development of a unified database to assess the incidence of myeloma in Asian countries to formulate the design of a region-specific treatment management plan. The IMF will provide help



establishing this database with the creation of a template for data entry. Intended future projects will include the establishment of Asian clinical trials, as well as the development of informational resource materials in local languages, based on previous IMF-produced materials, intended for patients and caregiver use.





Wee Joo Chng, MD, PhD National University Cancer Institute of Singapore, National University Health System, Singapore

Dr. Chng began his work in myeloma at the Mayo Clinic in Arizona in 2004. His present work in the field is around disease biology and risk assessment of patients in order to identify best possible therapeutic avenues, customized to individual patient needs.

"I was always interested in myeloma because of its complexity, its challenging nature, and because myeloma is at the forefront of the genomic revolution – an exciting area for drug development in hematologic malignancies."

Dr. Chng was first introduced to the IMF during his fellowship at the Mayo Clinic in 2005. The range of researchers working within the organization and its involvement of patients and families into the realm of cancer research are what drew him to the IMF. He later joined the IMWG, where he worked on the study of the survival among novel agent-treated myeloma patients who relapsed and the consensus statement on the role of risk stratification in myeloma treatment. He has also been working with Dr. Munshi of the Dana Farber Cancer Institute on a gene expressions analysis that promises to strengthen prognostics.

"Being part of the IMWG brought me closer to a community of thought leaders in the field. The frequent interaction and collaboration have greatly informed my practice in the management of myeloma patients in Singapore. My role in the IMWG has allowed me to participate in charting the future course of research and clinical management of myeloma."

Dr. Chng, with the help of the IMF, has started patient education initiatives in Singapore and recently organized the first patient forum in Singapore. It is his hope that the IMF's presence in Asia will grow and will strengthen our understanding of epidemiologic variations across ethnic groups in the myeloma community.

Robert A. Kyle Lifetime Achievement Award

Named for its first recipient, the Robert A. Kyle Lifetime Achievement Award is presented annually by the IMF to an individual whose body of work in the field of myeloma has



made significant advances in research, treatment, and care of myeloma patients.

NINTH ANNUAL INTERNATIONAL MYELOMA FOUNDATION ROBERT A. KYLE LIFETIME ACHIEVEMENT AWARD



Douglas Joshua, AM received this year's award. He is Head of Clinical and Laboratory Haematology at Sydney Cancer Centre, Head of Sydney South Western Area Health Service Haematology, the Alan Ng Professor in Medicine at University of Sydney, and the Director of the Institute of Hematology, Royal Prince Alfred Hospital. Professor Joshua is the ninth Kyle Award winner, and was honored in London on June 8, 2011.

IMF Research-focused Presentations/Symposia at 2011 Myeloma Research-related Global Conferences

The International Myeloma Workshop

The International Myeloma Workshop, which took place in May 2011 in Paris, France, focused on the biology, genetics, diagnosis, and treatment of multiple myeloma. The IMF held a seminar on key findings of this conference on May 6, facilitated by Brian Durie, Xavier LeLeu, Jean Fermand, and Thierry Facon.

Topics included:

- New data around long-term continuous lenalidomide maintenance therapy following stem cell transplants (seen to delay disease progression and improve overall survival)
- Pomalidomide and carfilzomib moving closer to FDA approval

The American Society Of Hematology (ASH)

The American Society Of Hematology (ASH), which was held in December 2010 in Orlando, Florida, featured multiple myeloma as a key topic. On December 3, the IMF and the Postgraduate Institute for Medicine sponsored a symposium featuring the most recent reported observations from clinical trials of new drugs in development and combination therapies:

New drugs discussed at the IMF-sponsored symposium

- Carfilzomib, a proteasome inhibitor, shows promising activity among relapsed/refractory myeloma in phase I of a three-phased Multiple Myeloma Consortium study
- Pomalidomide, a promising immunomodulatory drug, is undergoing studies to determine best dosage practices
- Elotuzumab, a humanized monoclonal antibody, shows positive activity in a clinical trial; further research is required to look into effective dosage levels.
- MAbs in development: mapatumumab and lexatumumab

Combined regimens discussed

- Weekly bortezomib in combination with temsirolimus has shown positive activity
- A phase I trial is underway to assess dual targeting of -TORC1 and -TORC2
- An evaluation of lenalidomide and PD-0332991 showed an additive effect on reduction of IRF4, a myeloma survival cell factor.

The symposium concluded with a discussion on how these novel agents and new drug regimens are evolving. The trend of increased survival for patients with myeloma that began in the era of novel agents is continuing. Future regimens are likely to be based on combination therapies with unique mechanisms of action and non-overlapping toxicities. Risk stratification and tailoring of therapy to individual needs is advancing to include patient quality of life.

Brian D. Novis Research Grants

Through its Brian D. Novis Research Grants program, the IMF remains at the forefront of identifying, supporting, and developing the world's most promising myeloma research. The IMF backs both junior and senior researchers, funding 111 grants since the program's inception in 1994. This IMF-supported work, which has led to more than 250 publications in the world's top research journals, continues to build knowledge around this disease and its treatment.



Brian D. Novis Senior Research Grants 2011

In memory of the IMF's co-founder, Brian Novis, the IMF has established annual grants to promote research into better treatments, management, prevention, and a cure. These grants are made possible through donations from private individuals and are awarded annually to doctors and researchers of promising work in the field of myeloma.

Laurence Catley, VIBBS, FRACP, FRCPA

Mater Medical Research Institute Cancer and Immunology Program South Brisbane, Australia *Metabolic targeting therapy for multiple myeloma*

Hearn J. Cho, MD, PhD

New York University School of Medicine New York University Cancer Institute New York, NY, USA *Rationally designed pralatrexate combination therapies for multiple myeloma*

Brian D. Novis Junior Research Grants 2011

Shirong Li, PhD

University of Pittsburg Division of Hematology/Oncology Pittsburg, PA, USA *Targeting the translational machinery in multiple myeloma*

Naoya Mimura, MD, PhD

Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School Boston, MA, USA **Targeting the IREa-XBPI pathway in multiple myeloma**

Vyacheslav Yurchenko, PhD

Rockefeller University Laboratory of Lymphocyte Signaling New York, NY, USA *MMSET and epigenetic control in t(4;14) myelomas*

The 9th Annual Aki Horinouchi Research Grant

Instituted by IMF-Japan in memory of its founder, this annual award has funded nine important research projects from 2002 to 2010 and two myeloma clinical group studies. The 2011 grant was awarded to two projects, for the first time since its inception:

Hiroshi Yasuim, MD, PhD

Sapporo University School of Medicine Sapporo, Japan

Epigenetics in multiple myeloma and prospects for translational research

Yusuke Furukawa, MD

Jichi University School of Medicine Tochigi-ken, Japan *The role of histone deacetylases* (HDAC) in drug resistance of multiple myeloma cells



Hearn Jay Cho, MD, PhD New York University School of Medicine New York, NY

Dr. Cho was introduced to the field of myeloma research by a teacher and leading clinician in the field, Dr. Josi Michaeli. Through their collaborative work, Dr. Michaeli passed on to Dr. Cho his passion to eliminate this disease.

Dr. Cho has been a friend of the IMF for years and pursued the Brian D. Novis Senior Research Grant to investigate the effectiveness of pralatrexate for use in relapsed T-cell lymphoma. This class of anti-folate drug has not been commonly used in myeloma, but Dr. Cho's work has shown its effectiveness in lab trials. His work with this novel therapeutic agent and his work on vaccine immunotherapy is greatly contributing to superior treatment strategies and targeted therapeutic approaches.

"The IMF is an organization of dedicated and passionate people, and their efforts are a critical complement to the clinical and translational research side of the myeloma field. We all have the same goal, and we all contribute to that goal. Independent funding agencies such as the IMF play a critical role in biomedical research and the IMF ensures that myeloma researchers will continue to receive funding to advance the search for a cure."

IMF Scientific Advisory Board

Robert A. Kyle, MD, Chairman Mayo Clinic Rochester, MN, USA Kenneth C. Anderson, MD

Dana-Farber Cancer Institute Boston, MA, USA

Michel Attal, MD Hôpital Purpan Toulouse, France

Hervé Avet-Loiseau, MD, PhD Institute de Biologie Nantes, France

Dalsu Baris, MD, PhD National Cancer Institute Rockville, MD, USA

Bart Barlogie, MD, PhD Myeloma Institute for Research and Therapy Little Rock, AR, USA

Régis Bataille, MD Central Laboratory of Hematology Nantes, France

Meral Beksaç, MD Ankara University Ankara, Turkey

William Bensinger, MD Fred Hutchinson Cancer Research Center Seattle WA LISA

P. Leif Bergsagel, MD Mayo Clinic

Scottsdale, AZ, USA Joan Bladé, MD Hospital Clinic

Barcelona, Spain Mario Boccadoro, MD University of Torino

Torino, Italy Michele Cavo, MD Univeristy of Bologna Bologna, Italy

J. Anthony Child, MD University of Leeds Chichester, UK

Raymond L. Comenzo, MD Tufts Medical Center Boston MA USA

John Crowley, PhD Cancer Research and Biostatistics Seattle, WA, USA

Franco Dammacco, MD Institute of Clinical Medicine Bari. Italy

Faith Davies, MD Royal Marsden Hospital London Sutton, UK

Meletios Dimopoulos, MD University of Athens Athens, Greece

Johannes Drach, MD University of Vienna Vienna, Austria

Brian G.M. Durie, MD Cedars-Sinai Samuel Oschin Cancer Center Los Angeles, CA, USA

Hermann Einsele, MD University of Würzburg Würzburg, Germany

Thierry Facon, MD Hopital C. Huriez Lille, France

Dorotea Fantl, MD Sociedad Argentinade Hematolgia Buenos Aries, Argentina

Jean-Paul Fermand, MD Hopital Saint-Louis Paris. France

Rafael Fonseca, MD Mayo Clinic Scottsdale, AZ, USA **Gösta Gahrton, MD** Huddinge University Hospital Stockholm, Sweden

Morie A. Gertz, MD Mayo Clinic Rochester, MN, USA

John Gibson, MD Royal Prince Alfred Hospital Camperdown, Australia

Hartmut Goldschmidt, MD University of Heidelberg Heidelberg, Germany

Roman Hájek, MD University Hospital Brno Brno, Czech Republic

Joy Ho, MD Royal Prince Alfred Hospital Camperdown, Australia

Vania Hungria, MD Clinica São Germano São Paulo, Brazil

Sundar Jagannath, MD The Mount Sinai Medical Center New York, NY, USA

Douglas Joshua, MD Royal Prince Alfred Hospital Camperdown, Australia

Michio M. Kawano, MD Yamaguchi University Ube Japan

Ola Landgren, MD, PhD National Cancer Institute, National Institutes of Health Bethesda, MD, USA

Henk M. Lokhorst, MD University Hospital Utrecht Utrecht, Netherlands

Sagar Lonial, MD Emory Winship Cancer Institute Atlanta, GA, USA

Heinz Ludwig, MD Wilhelminenspital Vienna, Austria

Jayesh Mehta, MD Northwestern University Chicago, IL, USA

Håkan Mellstedt, MD, PhD Karolinska Hospital Stockholm, Sweden

Giampaolo Merlini, MD University of Pavia Biotechnology Research Laboratories Pavia, Italy

Angelina Rodriguez Morales, MD Hemato-Oncology Clinica Caracas, Venezuela

Gareth Morgan, MD, PhD Royal Marsden Hospital Sutton, UK

Nikhil Munshi, MD Dana-Farber Cancer Institute Boston, MA, USA

Amara Nouel, MD Hospital Rutz y Paez Bolivar, Venezuela

Antonio Palumbo, MD University of Torino Torino, Italy

Linda Pilarski, MD University of Alberta Edmonton, AB, Canada

Raymond Powles, MD Parkside Oncology Clinic London, UK

S. Vincent Rajkumar, MD Mayo Clinic Rochester, MN, USA **Donna E. Reece, MD** Princess Margaret Hospital Toronto, Canada

Paul G. Richardson, MD Dana-Farber Cancer Institute Boston, MA, USA David Roodman, MD

Indiana University School of Medicine Indianapolis, IN, USA

Jesús F. San-Miguel, MD University of Salamanca Salamanca, Spain

Rik Schots, MD Universitair Ziekenhuis Brussel Brussels, Belgium

Orhan Sezer, MD University of Hamburg Hamburg, Germany

Kazayuki Shimizu, MD University of Keio for Advanced Biosciences Tsuruoka, Japan

Chaim Shustik, MD McGill University Montreal, QC, Canada

David Siegel, MD Hackensack University Medical Center Hackensack, NJ, USA

Seema Singhal, MD Northwestern University Medical Center

Chicago, IL, USA Alan Solomon, MD University of Tennessee Medical Center Knoxville, TN, USA

Pieter Sonneveld, MD, PhD Erasmus Medical Center Rotterdam, The Netherlands

Andrew Spencer, MD The Alfred Hospital Melbourne, Australia

A. Keith Stewart, MD Mayo Clinic Scottsdale, AZ, USA

Guido Tricot, MD University of Utah Huntsman Cancer Institute Salt Lake City, UT, USA

Benjamin Van Camp, MD, PhD Vrije Universiteit Brussel Brussels, Belgium

Brian G. Van Ness, MD, PhD University of Minnesota Minneapolis, MN, USA

David H. Vesole, MD John Theurer Cancer Center at Hackensack University Medical Center Hackensack, NJ, USA

Jan Westin, MD Sahlgrenska University Hospital Göteborg, Sweden

Emeriti

Raymond Alexanian, MD USA

Y.C. Chen, MD Republic of China

lan Franklin, MD Scotland, UK

Tadamitsu Kishimoto, MD Japan

lan MacLennan, MD England, UK

James S. Malpas, MD England, UK

Martin M. Oken, MD

RESEARCH

Global Clinical Trials Forum

The IMF's Global Clinical Trials Forum was created to enhance the collaboration and cooperation between national and international myeloma research groups in order to improve clinical trial design and data accrual. In December 2010, the Global Clinical Trials Forum convened at the ASH conference in Orlando, Florida, where myeloma and new drug development around myeloma were featured topics.

The European Myeloma Network gave a presentation at this forum, which provided the audience an overview of their work and highlighted their interest in collaborating with clinical trial groups outside the European Union. For the first time, Asian myeloma experts attended this discussion with other world experts and were impressed with the structure and idea to establish a network of countries to focus on clinical trial endeavors. This exhibits growth of the IMF's reach around the globe.

Global Clinical Trials Forum

Kenneth C. Anderson, MD Dana-Farber Cancer Institute Boston, MA, USA

Michel Attal, MD Service d'Hematologie, Hospital Purpan Toulouse, France

Hervé Avet-Loiseau, MD Institutes of Biologie Nantes, France

Bart Barlogie, MD Myeloma Institute for Research Therapy Little Rock, AR, USA

William Bensinger, MD Fred Hutchinson Cancer Research Center Seattle, WA, USA

Joan Bladé, MD Hospital Clinica Barcelona, Spain

Ivan Borrello, MD Johns Hopkins University Baltimore, MD, USA Wee Joo Chng, MD National University of Singapore Singapore

John Crowley, PhD Cancer Research and Biostatistics Seattle, WA, USA

Angela Dispenzieri, MD Mayo Clinic Rochester, MN, USA

Brian G.M. Durie, MD Cedars-Sinai Samuel Oschin Cancer Center Los Angeles, CA, USA

Morie A. Gertz, MD Mayo Clinic Rochester, MN, USA

Sergio Giralt, MD Memorial Sloan-Kettering Cancer Center New York, NY, USA

Roman Hajek, MD University Hospital Brno Brno, Czech Republic Sundar Jagannath, MD The Mount Sinai Cancer Instittue New York, NY, USA

Shaji Kumar, MD Mayo Clinic Rochester, MN, USA

Robert A. Kyle, MD Mayo Clinic Rochester, MN, USA

Jae-Hoon Lee, MD Gachon University Gil Hospital Incheon, Republic of Korea

Richard F. Little, MD National Cancer Institute Bethesda, MD USA

Sagar Lonial, MD Winship Cancer Institute Atlanta, GA, USA

Heinz Ludwig, MD Wilhelminenspital der Stadt Wien Vienna, Austria Gareth Morgan, MD, PhD Royal Marsden Hospital Sutton, UK

Nikhil Munshi, MD Dana-Farber Cancer Institute Boston, MA, USA

Antonio Palumbo, MD University of Torino Torino, Italy

S. Vincent Rajkumar, MD Mayo Clinic Rochester, MN, USA

Donna Reece, MD Princess Margaret Hospital Toronto, ON, Canada

Jésus San Miguel, MD University of Salamanca Salamanca, Spain

Seema Singhal, MD Northwestern University Medical School Chicago, IL, USA **Pieter Sonneveld, MD, PhD** Erasmus Medical Center Rotterdam, The Netherlands

Edward Stadtmauer, MD University of Pennsylvania Philadelphia, PA, USA

Howard Streicher, MD National Cancer Institute Rockville, MD, USA

Robert Vescio, MD Cedars-Sinai Samuel Oschin Cancer Center Los Angeles, CA, USA

Our collaborative research extends worldwide.



In this bird's-eye view, the colored dots represent the locations where IMF research programs take place all around the globe.

9



John Lively Dallas, TX

In January 1996, John Lively was diagnosed with monoclonal gammopathy of undetermined significance (MGUS). He had little understanding of what this diagnosis meant for him and contacted the National Cancer Association, which sent him literature illustrating the high fatality rate associated with the disease. His healthcare providers put him in touch with the IMF. The IMF sent him resource materials and contact information for Peter Tischler, who ran a support group in his area. John has been a member and facilitator of this support group ever since.

There is no treatment for MGUS; rather it's a condition his healthcare providers will regularly monitor. He attended his first Patient & Family Seminar in Atlanta, Georgia in the spring of 1997. There he had the opportunity to speak with Drs. Durie and Kyle, Susie Novis, and several myeloma patients. He left that seminar knowing that there was no cure, but that he has a long life to live. He renewed his pilot license and flew all over the country. Today he goes dancing three to six nights a week. He has owned his own business since 1969, and has no plans to retire. He is 70 years old.

John takes comfort in staying knowledgeable about myeloma and the promising novel agents and therapy regimens in pursuit to treat it. "This disease has come from no hope, to a chronic disease that can be cared for with some bumps in the road."

He continues to attend Patient & Family Seminars when they are in the Dallas area and is grateful for the opportunity to further his knowledge of the disease as well as give and receive support to other patients living with myeloma. "By attending the Patient & Family seminars, I know I don't walk alone with this disease. The IMF has been a part of my family. If I have a question they are only a phone call away. I have supported them all these years and they have supported me. In our support group we are always hearing from patients who have contacted the IMF with their questions and get more back than they expected. The IMF, Dr. Durie, Susie are a part of our family. I tell people in my situation to not hesitate to make that phone call."

EDUCATION

Although myeloma is one of the most prevalent forms of blood cancer, prior to diagnosis few patients have heard of the disease. To help address the many questions those newly affected by myeloma have, the IMF works to continuously share information on care, treatment, and support through the workshops and publications mentioned below. The IMF is also dedicated to supporting myeloma health care professionals with up-to-date information on treatment through its Nurse Leadership Board (see page 13).

IMF educational support gives patients an opportunity to join health care providers in decisions around treatment, creating the best possible quality of life for every myeloma patient.

IMF Patient & Family Seminars



The IMF's Patient & Family Seminars present vital information about new treatments and clinical trials, provide time with myeloma specialists in intimate settings, and allow participants to share personal experiences and support. Premier myeloma experts

volunteer their time to the seminars, to empower patients and their families to make educated treatment choices tailored to their needs.



Since 1993, the IMF has hosted over 200 Patient & Family Seminars in 16 countries. From October

2010 to September 2011, approximately 1,000 participants attended US-based seminars in San Francisco, CA; Dallas, TX; Boca Raton, FL; and Philadelphia, PA.

Internationally, approximately 1,300 people attended IMF Patient & Family Seminars in Barcelona, Spain; Göteborg, Sweden; Hamburg, Heidelberg, and Würzburg, Germany; Lednice, Czech Republic; Lucca, Italy; Oslo, Norway; Rome, Italy; and Vienna, Austria.

Regional Community Workshops



In addition to Patient & Family Seminars, the IMF facilitates Regional Community Workshops, which serve as condensed seminars in smaller cities to expand the reach of IMF programs and up-to-date information on myeloma care, support, and treatment to a wider audience. From October 2010 to September 2011, 12 US-based workshops were held

in Shreveport, LA; Denver, CO; Las Vegas, NV; Raleigh, NC; Kansas City, KS; San Diego, CA; Atlanta, GA; Jacksonville, FL; Detroit, MI: Hartford, TX; Minneapolis, MO; and Norfolk, VA and were attended by approximately 960 participants.

The IMF also facilitated international Community Workshops, which attracted more than 400 participants in Berlin, Koblenz, and Leipzig, Germany; and Prague, Czech Republic.



EDUCATION

International Education

Community Workshops and Roundtables for more than 130 clinicians and researchers were held in Bergen, Norway; Berlin and Heidelberg, Germany; Göteborg, Lund, and Stockholm, Sweden; and Trondheim, Norway.

IMF Board Member and Scientific Advisory Board Chair Dr. Robert Kyle participated in meetings in Berlin, Göteborg, Heidelberg, Koblenz, Lund, Sweden, and Oslo. IMF Founder and Chairman Dr. Brian Durie spoke in Rome, Stockholm, and Vienna. IMF Scientific Advisory Board member Dr. Bart Barlogie was featured in Berlin, Heidelberg, Stuttgart, and Würzburg. All three are members of the International Myeloma Working Group (IMWG).

Publications

The IMF is committed to the production of written materials that provide the myeloma community with an extensive knowledge base. The IMF's catalogue of materials includes a wide-ranging collection of communications materials, such as informational brochures and tip cards for patient and provider use, and journal articles which contribute to the body of knowledge of the latest research in the field of myeloma. This



library is also home to the IMF's quarterly produced newsletter, *Myeloma Today*, and its email-based newsletter the *Myeloma Minute*, both of which provide up-to-date information on all issues affecting the myeloma community, including innovations in treatment, information on clinical trials, updates on policy issues, and guidance on where support can be accessed. All of these materials are produced by the IMF with oversight by its Scientific Advisory Board. The IMF library's broad scope includes information about myeloma treatment options, clinical trials, and quality of life considerations for patients and physicians. IMF publications are provided free of charge, in 16 languages.

From October 2010 through September 2011, the IMF created seventeen new publications. Seventeen additional publications were updated with the latest information. Many of these are bundled into the IMF InfoPack, designed to provide newly diagnosed patients and their families with complete understanding of the disease and patient care. From October 2010 to September 2011, the IMF disseminated approximately 2,200 InfoPacks to patients, health care providers, and support groups around the world.

The IMF's *Myeloma Today* is one of the few resources in the world which provides regularly updated information on advances in treatment, research, and quality of life. This newsletter has a readership estimated at 75,000 per issue.

The *Myeloma Minute* provides up-to-the-minute information about research, events, and IMF programs. In September 2011, its subscriber-base was nearly 30,000 readers.

IMF 2011 List of Publications

CITINGS: ASCO 2011 - Novel Therapies - Special Edition* CITINGS: ASCO 2011 – Freelite[®]/Hevylite[™] – Special Edition* CITINGS: ASH 2011 - Novel Therapies - Special Edition* CITINGS: ASH 2011 – Freelite[®]/Hevylite[™] – Special Edition* CITINGS: Freelite[®]/Hevylite^{™**} CITINGS: Novel Therapies** CITINGS: Novel Therapies - March 2011* CITINGS: Novel Therapies - May 2011* Clinical Trial Data Sheets: ASPIRE and FOCUS trials* Concise Review of the Disease and Treatment Options** Early Screening for MGUS flowchart* Freelite[®] tip card* ASCO 2011 Highlights for Patients* ASCO 2011 Highlights for Physicians* ASH 2010 Highlights for Patients* ASH 2010 Highlights for Physicians* I Have Myeloma...What's Next? (DVD) IMF Patient & Family Seminar: Boca Raton 2011 (DVD)* International Myeloma Workshop: Paris 2011 (set of 4 DVDs)* International Myeloma Workshop: Paris 2011 – Comprehensive Guide* IMF Patient Handbook** International Myeloma Working Group (IMWG) publications (a total of 39 as of 9/30/11) International Staging System tip card MM Support Group tip card** Monitoring Patients with M-Proteins flowchart Mozobil® tip card Multiple Myeloma tip card Myeloma Manager[™] tip card Myeloma Matrix: Clinical Trials** Myeloma Minute e-newsletter** Myeloma Today quarterly newsletter** Nurse Leadership Board Survivorship Care Guidelines* ONS Symposium 2011 (DVD)** Understanding Anemia and Fatique** Understanding Balloon Kyphoplasty and Myeloma-Induced Vertebral Compression Fractures Understanding Bisphosphonate Therapy** Understanding Dexamethasone and other Steroids** Understanding Protein Electrophoresis* Understanding Revlimid®** Understanding Serum Free Light Chain Assays** Understanding Stem Cell Transplant** Understanding Thalidomide Therapy** Understanding VELCADE (bortezomib) for Injection Therapy** Understanding Your Test Results* *New for 2011

**Updated for 2011



Tiffany Richards, MS, ANP, AOCNP Houston, TX

Since 2004, Tiffany Richards has focused her career in nursing on the care and support of patients with myeloma. In an effort to increase education of myeloma and its treatment among patients and caregivers, Tiffany reached out to support groups and began presenting at an IMF-led support group in her community. Through her relationship with this group and with the IMF, Tiffany was introduced to the work of the Nurse Leadership Board (NLB) and has become an invaluable member.

At the sixth annual NLB meeting in November 2010, Tiffany gave a lecture entitled *Impact of Myeloma Disease, Treatments, Long-Term Effects, and Patient-Specific Characteristics on Renal Complications, Sexuality, and Sexual Dysfunction.* In her words, "Sexual dysfunction is one of the most common and enduring consequences of cancer treatment and one that is not often addressed." She pleaded for increased communication among patients, nurses, and physicians in this area to increase patient quality of life.

Currently, Tiffany sits on the NLB publications committee and is chairing the survivorship tool committee. She feels that the work she accomplishes through the NLB is immensely valuable.

"The NLB works to educate nurses on how to managepatients with myeloma, which is incredibly important. Most nurses are not familiar with the disease, but I see this beginning to change."



Nurse Leadership Board

The IMF Nurse Leadership Board (NLB) is comprised of 20 nurses from major centers treating myeloma patients throughout the US. The NLB provides a forum for addressing the needs of the myeloma nurse and patient communities. NLB members work each year to provide relevant information to patients and

providers by presenting at key conferences, participating in IMF Patient and Family Seminars and Regional Workshops, conducting nurse education webinars and other educational teleconferences and through publication of educational materials and guidelines on myeloma management.

In November 2010, the NLB convened its sixth annual meeting in New Jersey, where NLB members discussed their projects including publication and dissemination of the Survivorship Care Plans for Myeloma Patients, development of a web-based survivorship tool, design and implementation of nurse-led research, and developing guidelines for care of the myeloma patient undergoing transplant.

In April 2011, the NLB hosted a symposium at the 36th Annual Congress of the Oncology Nursing Society to present the NLB Long Term Care Survivorship Guidelines for Multiple Myeloma Patients. The symposium focused on promising agents in clinical development, optimal patient treatments, follow-up of treatment outcomes, and how to maintain quality of life through this continuum of cancer and treatment. This conference was attended by 750 nurses.

IMF Nurse Leadership Board Members

Page Bertolotti, RN, BSN, OCN Cedars-Sinai Outpatient Cancer Center Samuel Oschin Comprehensive Cancer Institute Los Angeles, CA

Elizabeth Bilotti, RN, MSN, APRN, BC, OCN The John Theurer Cancer Center at HUMC Multiple Myeloma Division Hackensack, NJ

Kathleen Colson, RN, BSN, BS Dana-Farber Cancer Institute Boston, MA

Deborah Doss, RN, OCN Dana-Farber Cancer Institute Boston, MA

Beth Faiman, MSN, APRN-BC, AOCN Cleveland Clinic Taussig Cancer Institute Multiple Myeloma Program Cleveland. OH

Charise Gleason, MSN, NP-BC, AOCNP Emory University Winship Cancer Institute Atlanta, GA

Bonnie Jenkins, RN University of Arkansas Medical School Little Rock, AR Kathy Lilleby, RN Fred Hutchinson Cancer Research Center Seattle, WA

Patricia A. Mangan, APRN, BC Abramson Cancer Center University of Pennsylvania Philadelphia. PA

Ann McNeill, RN, MSN, APN

The John Theurer Cancer Center at HUMC Multiple Myeloma Division Hackensack, NJ

Teresa Miceli, RN, BSN, OCN Mayo Clinic Rochester Rochester, MN

Kena C. Miller, RN, MSN, FNP Roswell Park Cancer Institute Buffalo, NY

Tiffany Richards, MS, ANP, AOCNP MD Anderson Cancer Center Houston, TX

Sandra Rome, RN, MN, AOCN Cedars-Sinai Medical Center Los Angeles, CA **Jacy Spong, RN, BSN, OCN** Mayo Clinic Arizona Scottsdale, AZ

Joseph D. Tariman, PhD, APRN, BC Northwestern University Myeloma Program Chicago, IL

NLB Associate Members

B. Nadine Baxter-Hale, MNSc, APN-BC, AOCNP

University of Arkansas for Medical Sciences Myeloma Institute of Research and Therapy Little Rock, AR

Elizabeth Finley-Oliver, RN H. Lee Moffitt Cancer Center and Research Institute Tampa, FL

Sandra Kurtin, RN, MS, AOCN, ANP-C Arizona Cancer Center Tucson, AZ

Kimberly Noonan, RN, ANP, AOCN Dana-Farber Cancer Institute Boston, MA

SUPPORT Myeloma may suck, but the IMF rocks.

- BARBARA HAMMACK, Kensington, MD

The IMF remains dedicated to ensuring the Support of those living with myeloma. The IMF's programs and services are designed to provide patients and their loved ones with local and global support networks and easily accessible, up-todate information. The IMF provides educational and psychosocial support of the myeloma community through its website, listserv, social media efforts, and its tollfree Hotline, as well as its wide-ranging network of community support groups.

myeloma.org

Through its website, the IMF offers patients, caregivers, and health care professionals multi-lingual access to the IMF and externally published literature, research updates, the latest community developments, and linkage to support services and advocacy forums. From October 2010 through September 2011, over



340,000 visitors went to myeloma.org,

tallying nearly 1,400,000 page views. Of these visitors, 60% were new to the IMF website. The almost 1,000 IMF-produced videos housed on the web brought nearly 58,000 views. Website visitors viewed and downloaded over 23,000 PDFs of documents created or updated during the year. During this time period, the IMF's website was also visited over 18,000 times from mobile devices.

Summer of 2011 saw the addition to the website of 10 Steps to Better Care[™], an interactive online, downloadable resource. Patients and caregivers can drill down into each step to read articles, watch videos, and gain a better understanding about everything from initial diagnosis, to relapse, tests, and clinical trials.



Toll-Free Hotline

The IMF's toll-free Hotline provides life-saving and lifechanging myeloma treatment and management support from highly trained specialists. From October 2010 through September 2011, Hotline responders supported 2,179 callers and answered nearly 1,500 emails.



Barbara Hammack Kensington, MD

In 1991, Barbara Hammack was told she "probably" had smoldering myeloma. At the time, Barbara (or Boogie, as she's often called) was 45, busy, career-focused, and not particularly well-informed by her then-provider. She went through the motions of this seemingly strange diagnosis and treatment. It was not until after multiple rounds of treatment (with the ensuing hair loss), and preparation for stem cell transplantation that Boogie realized she had cancer and that this cancer would greatly impact her life. She had her transplant in 1994. Her transplant and her treatment, although extremely difficult to live through, have been met with success.

Barb retired in 1999 and was looking for something meaningful to make of her time. She found a myeloma support group in her community and started to build relationships with other patients, caregivers, and the IMF. Soon after joining the group, she attended her first Patient & Family Seminar where she connected with an IMF Hotline coordinator. Over the years, Barb has stayed in close communication with the Hotline; it has proved an immense resource for Barb in understanding her disease.

"During my transplant in 1994, I didn't know about the IMF; I don't even think we had reliable internet then. I was living in a bit of a vacuum. I now have the opportunity to prevent that knowledge gap. I have referred countless patients to the IMF Hotline, knowing that they will be given the best information from the most caring people."

Today, Boogie is doing well. Her oncologist started her on an oral chemotherapy with promising outcomes in the first few months. She continues her volunteer work and her outreach and support of myeloma awareness, and her steadfast relationship with the IMF, because in her words *"Myeloma may suck, but the IMF rocks."*



Anne Pacowta Ponte Vedra, FL

In 2003, Jack Pacowta was diagnosed with myeloma. Soon after his diagnosis, Jack and his wife, Anne, learned of the IMF and a local IMF support group in their community of Waterbury, CT. They began to attend support group meetings and took some comfort in educating themselves about this disease and treatment innovations, as well as the personal support received there.

Jack retired in 2006 and he and Anne decided it was best to move down to Ponte Vedra, where they vacationed for years. In their new community, there were no myeloma-specific support groups and Anne and Jack realized the importance of the help provided through those meetings.

They reached out to the IMF and consulted with staff on how, where, and when to build their own support group. In December 2007, they held their first meeting, with twelve people in attendance.

Jack passed away in 2008. Before he died, he expressed his wish for the group to continue. Anne and her co-leaders, Hunter and Diana Chiles, have served Jack's legacy well; there are now 49 members of the North Florida Multiple Myeloma Support Group.

"Jack's diagnosis was both a devastation and blessing to our family. No other event in our lives made our priorities so very crystal clear and brought an already close family even closer. It's been three years that I've been carrying on his wish, and at times it becomes painful, but the ability to help someone take charge of their situation and be empowered by education is very gratifying. I made a commitment to continue as long as I can."

Support Groups

Through a global community of assisted support groups, the IMF seeks to ensure that patients and families have local access to psychosocial support and education. The IMF currently supports more



than 150 support groups worldwide. From October 2010 through September 2011, a total of nine new support groups were formed in: Dover, DE; Chico, CA; Grand



Rapids, MI; Nature Coast, FL; Texarkana, AR; Kingwood, TX; Indianapolis, IN; Charlotte, NC; and Nashville, TN

The IMF is dedicated to overseeing the needs of these groups and their leaders. From October 2010 through September 2011, IMF staff visited 95 percent of its US-based groups at least once.

In addition, the IMF's 12th annual Support Group Leaders' Summit took place in July 2011 in Dallas, TX. A total of 76 Support Group Leaders representing 50 groups attended the summit, including 33 leaders who attended for the first time. Participants



were updated on the latest information about myeloma treatment and care, and provided with new leadership tools and approaches – all to further enhance the experience for their support groups back home.

Myeloma Manager[™]

The IMF's Myeloma Manager[™] Personal Care Assistant[™] is a computer program that tracks a patient's individual laboratory results and also displays and prints charts to show how these results change over time. This is an unprecedented way for

e 14	Bende	Grapha C	Mandar	Costacte	Neter	(Inte					
244		Centres C		CLORECTE	raves		-				
<u>}</u>											
C	Inert	ab Resu	dia.								News A A
		WHEE OF		1/18/2000	4.0	-	114(2009	14	1.6	107	
		RED COLL		2 1/15/2303		-	114(2009)	2.6	1	÷.	Thursday, June 11, 2908
						100		2.74	6	1	Two New Support Groups in Columbus, Ohio and JuBois, Pennashania
		HEMDGLO.		0 1/15/2000		-	114(2009		1	-	If you live near Columbus or Dabols, check call these new support groups. They are be for reambars, Connect with others who traily know what you are eccentercies.
		HEV		0 1/18/2908			114(2009	103.5	4		TO TRADERISE COTTACE WITH DEVINE WITH TRAY WHEN WHE YOU ARE EXPERIENCED.
	MPLETE			9 1/18/2900			114(2000	25.9	4		Tuenday, June 49, 2004
	MPLETE			8 1/18/2908				100.0	2		ASCQ 2000 Webceata are senthe Web
er		REPORTED R		1/18,0309	71	ľ	114(2090	17	4	-	The 2850 ASCO Annual Heating was a forum for cvdirg-udge scandific and education developments is inciding with a focus or presentation guarant acro. We have aversis provided by Dis. Surie, Repurse and Anderson, as well as a rainteer of Monrievies well asteritish who preserved their results of the confinence.
U		ig Appoli			and	tote			_	_	Thursday, Van 38, 2004
	Date	0.00		Ubject		_	Туре		1	-	The International Maximum Foundation, the MDS Foundation and a Coalition of
-	(63)2			r Darie lav Cucla			Task	-	1		Patient Advocacy Organizations, Call for Updated Rales, for Relimitarsement,
1				lev 25mg			Taok			8	Accesse and Approvals for New and Scienting Cancer Treatments. A patient "Statement of Principles" was unveiled at the ADCO Heating in Driands. Field
-	67/04/2			lev 25mg			Tenh			-	The principles emphasize equal insurance coverage, prevention research, continued
120	07/01/2			les 40mg			Task			18	investion, carly oppression, and expended occess is experimental drugs. Click "Hare" I read the Principles and Red out have to receive year execut.
1				en 25mg			Tank				LINE DIA NUMBER AND LINE OF LINES OF HERMAN ACTS. WORDER
11	07/09/2	005		lev 15mg			Tank				Wednesday, May 27, 2000
10	07/04/3	809	ITT P	lev 25mg			Task			*	Conservers Statement and Goldelines Reserves the Cornert Role of Investor

patients to fully understand their own personal trends and assess progress over an extended period, helping them and their caregivers maximize the growing wealth of information and constantly increasing complexity of myeloma treatment programs.

The Myeloma Manager is available for download, free of charge, through the

IMF website. From October 2010 through September 2011, this groundbreaking program was downloaded for new use 1,443 times, with an additional 50 downloads of the amyloidosis-specific version of the program.

ADVOCACY

The IMF is dedicated to creating an inclusive community that supports the wideranging needs of all affected by myeloma. By advocating at state and federal levels, the IMF serves as a voice to heighten quality access to care and end disparities in insurance coverage that affect patient care, protect and increase myeloma research budgets, strengthen clinical trials, and advocate for prompt Food and Drug Administration approval of effective treatments. The IMF includes the entire myeloma community in these efforts and continues to expand its commitment to empowering patients, families, and friends to advocate on behalf of patient rights.

Public Policy

At the governmental level, the IMF remains committed to creating effective and prompt solutions, while simultaneously strengthening care strategies, cancer prevention, and treatment innovations. The IMF advocacy efforts have included calling on the US Congress to strengthen preventive care, improve patient access to treatment, and maintain the key provisions of health reform essential for high quality of care for cancer patients.



Despite the difficult economic times our

country faced in 2011, the IMF successfully advocated for the funding of important cancer research through government agencies. These efforts resulted in funding for programs at the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the US Centers for Disease Control and Prevention (CDC) in fiscal year 2011.

Advocacy Efforts at the Federal Level

This year, the IMF advocacy team focused on collaborating with a variety of cancerfocused patient organizations with a common goal: to increase access to treatment. In July 2011, the IMF formed the Patients Equal Access Coalition (PEAC), as a vehicle to achieve this goal. PEAC is comprised of advocacy groups from across the cancer spectrum, including breast, colorectal, ovarian, pancreatic, brain, myeloma, and other blood cancers.

PEAC supported Representative Brian Higgins (D-NJ) in



championing cancer issues in Congress and reintroducing the *Cancer Coverage Parity Act of 2011*. This important legislation is instrumental in making progress to eliminate the disparity in insurance coverage and reimbursement between oral and intravenous chemotherapy treatment, and to decrease the unmanageable out-ofpocket expenses for patients who have been prescribed an oral medication by their doctors.



Sue Enright Jackson, WI

"Nobody should have to max out their credit cards, or lose their home just to afford cancer treatment. Sadly, that is a reality for many cancer patients. They have enough on their plate just trying to regain their health without the added burden of figuring out how to pay for life-saving treatment and going deeply into debt in the process."

- **Sue Enright** in support of the oral drug parity bill in Wisconsin

Sue Enright, a caregiver and IMF advocate, has been lending her voice to support patient rights in Wisconsin. She co-founded the West Bend Myeloma Support Group in 2008 and later became a charter member of the Wisconsin Coalition for Cancer Treatment Access (WCCTA).

In January 2011, Sue and her husband Rob, a myeloma patient, along with three other members of their support group met with Wisconsin Representative Pat Strachota. They emphasized the importance of equal access to anticancer treatments for all patients. The group presented an overview of multiple myeloma, its treatments, and side effects.

Shortly after their meeting, Representative Strachota helped to introduce an oral chemotherapy access bill to ensure that insurance plans reimburse oral anticancer medications on the same basis as IV or injected anticancer medications.

In April 2011, Sue was part of a small but powerful group of IMF advocates for a *Day at the Capitol*, a lobby event hosted by the IMF, WCCTA, and the Leukemia and Lymphoma Society. The group of six met with three State Representatives and one State Senator to encourage the passage of the oral chemotherapy access bill in Wisconsin.

Sue hosted her second support group meeting with a member of the Wisconsin legislature, Senator Glenn Grothmann in August 2011. In all of these meetings, the group illustrated the importance of patient-physician collaboration in designing an effective treatment regimen and how inequity in coverage should not play a factor in those careful and life-saving discussions.

Sue calls her work a privilege. She looks forward to a brighter future for all cancer patients. Sue was recently voted *IMF Advocate of the Month* twice.

Advocacy Partnerships

In May 2011, the IMF once again participated in the One Voice Against Cancer (OVAC) Lobby Day in Washington, DC, organized to urge the federal government to increase funding for medical research at the NIH, NCI, CDC, and the FDA. In addition to its collaboration with OVAC, from October 2010 through September 2011, the IMF continued our partnerships with the Cancer Leadership Council, the Hematological Cancers Coalition, the Lethal Cancer Coalition and the National Coalition for Cancer Research, Alliance for a Stronger FDA and the National Organization for Rare Disorders, and formed a new partnership with the Wisconsin Coalition for Cancer Treatment Access.





IMF Advocacy Partners

- Alliance for a Stronger FDA
- Cancer Leadership Council
- Hematological Cancers Coalition
- Lethal Cancer Coalition
- National Coalition for Cancer Research
- National Organization for Rare Disorders
- One Voice Against Cancer
- Patient Equal Access Coalition
- Wisconsin Coalition for Cancer Treatment Access.

Advocacy Efforts at the State Level


Cancer treatment coverage legislation has been introduced in multiple states across the country and many IMF advocates turned out to support state bills and share their stories of how disparity in treatment access has affected their lives.

In March, myeloma survivor and IMF advocate David Cowan from New Mexico shared his story before the House, Health, and Government Affairs Committee in support of SB 385, which requires equal coverage for orally administered and intravenous chemotherapy in New Mexico. The bill passed unanimously and was signed into law in April 2011. In June, Paula Van Riper, an IMF Support



Group Leader from New Jersey, provided oral testimony on behalf of her group to support

David Cowan shared his story in New Mexico



Paula Van Riper



In Texas and Illinois the IMF issued action alerts to in-state network members, where chemotherapy access legislation was passed in May and July 2011 respectively. The IMF also worked with advocates to schedule meetings and encourage letters to state legislators in Pennsylvania, Oklahoma, and California to ensure the passage of this bill.

Kena Miller

IMF Advocacy Action Center

The IMF's Advocacy Action Center is an online, centralized hub that shares governmental activity affecting the myeloma community and provides the tools for myeloma patients, families, caregivers, and medical professionals to become part of the process.

From October 2010 through September 2011, nearly 1,000 new subscribers joined the IMF Myeloma Action Network, an email service that alerts members when a new government representative or legislative issue needs to be addressed by the myeloma community. Members of the Myeloma Action Network sent more than 3,000 emails to their state and federal legislators during this reporting period.

On August 11, 2011, the Action Center hosted a training webinar for all advocates that focused on the best ways to connect with Congress. This skills-building session was attended by more than 50 advocates and resulted in more than 10 face-to-face meetings with US Representatives across the country.

IMF Myeloma Awareness Month

The IMF advocates for research and treatment issues affecting the myeloma community by observing Myeloma Awareness Month. The March 2011 event included a four-part teleconference series, free of charge for all listeners. Topics addressed included an update on management of side effects treatments and novel agents, participations in clinical trials, issues of consideration in Medicare, and the psychosocial implications of myeloma.

ADVOCACY

DEVELOPMENT

You can either be frustrated your whole life, or try to create some semblance of understanding and do something about it. - STEVE FEIG, Miami, FL

The IMF's mission to improve lives and find a cure began 21 years ago with the belief that no one should ever have to face myeloma alone. The IMF's core programs in each of the four areas of research, education, support, and advocacy provide patients and their families with the most important tools to fight the disease.

These programs receive support through the IMF's relationships with individual donors, corporate sponsors, and grants from pharmaceutical partners. The results of the IMF's fundraising activities provide access to low- and no-cost programs and services to the myeloma community.

The IMF appreciates the support from all donors regardless of how large or small their gift may be. Each dollar received makes it possible to continue offering and improving upon existing programs, while exploring new ways to service the myeloma community with top-rate information and support.

During the 2010-11 Fiscal Year, the IMF exceeded its fundraising goals through the generous support of our donors. During the twelve-month period from October 1, 2010 to September 30, 2011, the IMF raised a total of \$9.2 million in support of vital programs and services.

Major Gifts & Planned Giving

The IMF received major gifts from 43 donors, totaling \$742,000 during the 2010-11 Fiscal Year. Major donors are a small but dedicated group of supporters who make a powerful impact on the IMF's fiscal stability through their generous and substantial gifts.

Brian D. Novis Legacy Society

The IMF recognizes individuals who have made arrangements to include the organization in their long-term estate plans through the Brian D. Novis Legacy Society. Members in the society make bequest provisions in their will or revocable trust, or name the IMF as a beneficiary of qualified retirement plan assets (IRA or 401(k)) or life insurance policy.



The IMF sincerely wishes long, happy, and healthy lives for all myeloma patients and their families, but also recognizes that this development strategy will yield long-term results to help ensure the future of the IMF's life-saving programs and services. To become a member of the Legacy Society, the IMF requests that individuals simply confirm their planned gift in writing. No minimum commitment is necessary.



Donna and Steve Feig Miami, FL

In 1991, Donna Feig's mother, Leta Garvett, was diagnosed with myeloma. Leta, a healthminded and resourceful person, took careful steps in her treatment. She joined an IMF Support Group soon after her diagnosis and initiated one of her own for her community of South Florida. Upon her passing, her husband, Robert, took it over. Robert Garvett not only ran the support group, but also leveraged funds for a research grant and helped coordinate a Patient & Family Seminar.

Donna and Steve Feig have a long and trusted relationship with the IMF and began giving to the IMF after Leta passed away. Their contributions and efforts on behalf of the IMF over the years, in particular their participation in the Annual Comedy Celebration, has had a major impact on the Foundation.

The Feigs hope their contributions will help patients and families the world over to benefit from the IMF-provided education and support from which their family benefitted. Donna is now a member of the IMF Board of Directors where she works to increase doctor- and patient-level education of this disease.

"In some way, both Donna and I have been very fortunate. In others, we've been very unfortunate. My child Clayton died at age 18, which is why we have created a Clayton Feig Research Grant. You can either be frustrated your whole life, or try to create some semblance of understanding and do something about it. We did the latter. The IMF stands for what we try to do."

– Steve Feig



Randy and Steve Tammara Philadelphia, PA

Randy Tammara's father, Steve, was diagnosed with myeloma at the age of 65. He's been battling this cancer, ostepenia, and anemia. He uses oral chemotherapy and supplements and he visits two oncologists on an alternating basis. Despite all of the challenges related to Steve's diagnosis, he shows up for work every day to help Randy run their co-owned pharmacy in Philadelphia, PA.

When it comes to receiving support for multiple myeloma, both Randy and Steve turn to the IMF. They value the up-to-date information provided through the IMF's educational and support resources. They also attend local support group meetings, through which their family has connected with care providers and other patients.

That is why both Randy and Steve support the IMF's mission through monthly giving. Their monthly donations were part of the inspiration behind creating the IMF's recurring giving program, The Hope Society. Their collective monthly support over the last five years has been considerable.

The IMF is grateful for this father and son team's generous dedication to its mission and hopes to continue to support Steve and the Tammara family in the management and care of myeloma.

The Hope Society

The IMF's sustained giving program allows members to make recurring contributions on a monthly or quarterly basis. Participants in this program make

small, regular donations that add up to make a significant impact on the organization's mission. Hope Society members gave a total of \$25,255 during the 2010-11 Fiscal Year, a 69% increase over last year.



The Hope Society Honor Roll

Kathy and Charles Albino Mary Ann and Jeffrey Allyn Cathie Alonzo **Bonnie Anderson** Deborah and John Anderson Pam and Scott Andrews Marv Authors **Elizabeth Beckley** David Bennett Marcy Bernstein John Boehle, Jr. Frances and James D. Bowles **Connie Brawley** Julia Brock David and Prudy Brown Patricia Vigilante and Robert Candela Annette and Patrick Cavanagh Anne Chapman Cynthia Ann and John Chmielewski Cynthia Clark David Cook Karen Countryman Maureen Cronin Carolyn and Monte Cunningham Franci Dale Myla De La Cruz Linda and Charles DeLong Brian Denver **Donald Detenber** Niall Doherty Joyce and James Donnell Rene DValery and James Baker Linda and Mark Edwards Joseph Daniel Ellis Kate and Douglas Farrell Donna and Lawrence Farrell Bernadette and Andrew Farrelly Virginia Field Donna Font Clara and Charles Francis Gallagher Dean Gallea Susan and Daniel Gannon

Gerda Ann Gassman Irene and Laurence Gauthier **Roseann and Philip Geiger** Patricia Giaimo Carl Gilliam Carla Goode Vivian Gould Roberta and Arnold Greenberg Janet and Randy Hagihara **Carol Hornreich** Nicci Hubert Carroll Anne and William Hynes Fileen and John Jammarino Judith Torrez and William Jewell Kathleen and David Johnson Steven M. Johnson Debbie and Jerry Jordan Sheila Kaplow **Eileen and Frank Kealty Rita and Robert Keating** Elise Ketner Roberta and Raymond Klein Leny and Ben Kolsteren Ann Nora Kruger Kristin and Scott La Berge Sharon Lackey Rose and George Leek Linda and Joseph Lerner Jean Novak and Mike LeTarte Kathleen and Charles Lewis Nancy and Don Lorenzen Mary Jane Lundy Helene and Alan Marks Laura McGlothin Marie Muccioli Karen and Edward Necela Barbara L. Neilon Marcelo Pakman Phyllis and Tom Parker Marlys and Ralph Peterson **Darlene Pickard** Joyce and Harold Piel

Agatha M. Polowy **Ellen Whitworth Powell** Dan Quattrochi Wilma and James Rector Lauren Regan Tina and Michael Rettig Linda and Jerry Reynolds Mary Alex Rohleder Heidi Rubinstein and Brian Kuchynskas **Robert Santos** Cynthia Schulze Marguerite and Daniel Scott **Diane Seccombe** Sherri and Say Sengsouvanna Fay and Henry* Shapiro Newton Sharp Nancy Shealy **Rachel Small** Randall Smith Ruth L. Spaulding Sandra M. Stokes Elizabeth and Frank Streff Nancy and Jay Style Dawn and Steven Switzer Henry B. Thomas Doris and James Thurau Nancy and William Tidwell Patricia and James Wagner Linda M. Wakefield Peter and Marcia Webber Jill and Mike Weiland Charlotte and Joseph Werkmeister Theresa and Phillip Westine **Becky and Charles Whitehead** Ray Andrew Wilkins David Wolf Sandy Kay Wytroval Julie and Van Zimmer

DEVELOPMENT

4th Annual Comedy Celebration

On November 13, 2010, almost 1,200 guests packed the Wilshire Ebell Theatre in Los Angeles for the IMF's 4th Annual Comedy Celebration benefiting the Peter Boyle

Memorial Fund, which supports the IMF's award-winning research program. The fundraiser raised nearly \$570,000 this year.

Loraine Boyle and returning co-chairs Amy and Steve Weiss once again rounded up an exceptional cast of comedians to come out in support of the IMF. As in previous years, the event was hosted by Ray Romano and featured appearances



from fellow Everybody Loves Raymond castmates Doris Roberts and Fred Willard, as well as Jeff Garlin from Curb Your Enthusiasm. In addition,



this year's show benefited from the talents of Dana Carvey, Carlos Mencia, Alex Trebek, Annette O'Toole, and Susie Essman, and a special musical performance by Dr. Ken Jeong and Mike O'Connell.

The IMF welcomed attendees to a pre-show cocktail party

and silent auction that made a significant impact on the overall success of the event. Items up for bid in the auction included a guitar

signed by Bruce

Springsteen, a





visit to 60 Minutes, and a fantastic assortment of trips, memorabilia, jewelry, and more that were graciously donated for the cause. VIP guests were also treated to a post-show champagne and dessert reception that lasted well into the night.

Member Fundraisers

Events held by IMF members around the country empower myeloma patients, their families, and their friends to make a difference on a community level. As the longest-running development program, Member Fundraisers have generated critical funds for the fight against myeloma through community events held nationwide.

IMF members held 63 events during the 2010-11 Fiscal Year, raising a total of \$397,400. Six of these events funded Brian D. Novis Research Grants a testament to the efforts of regular people with an extraordinary dedication to the IMF's mission.

The IMF is tremendously grateful to this incredibly dedicated and passionate group of members who have a profound effect on IMF programs, services, and research initiatives.



Rob Bradford Apopka, FL

IMF member Chris Hollyer touched the lives of many. In 2005, Chris ran both the Association of Cancer Online Resources and the IMF listserv. His vast knowledge of myeloma and its treatment, his kindness and his energy allowed him to reach thousands of patients throughout the world.

After Chris passed away in 2006, the outpouring of both admiration and grief from members of both online communities was overwhelming. Members wanted to find a way to thank and honor him for his commitment to help patients.

One couple in particular decided to put their words into action. In September 2006, Kim and Rob Bradford began hosting the annual Coach Rob Charity Golf and Benefit Bash to support a Brian D. Novis Research Grant in Chris' honor. At the time of the inaugural event, Rob had just completed two rounds of chemotherapy and a stem cell transplant to treat his multiple myeloma. This two-day event was then, and is now, a labor of love; it is a way for Rob and Kim to return the support that they were given while he was treated for myeloma.

"This event is a way to give back to all of the great people that assisted me in my time of need. It also supports finding a cure."

- Rob Bradford

In December 2011, Kim and Rob Bradford's efforts resulted in a Brian D. Novis Junior Grant awarded to Dr. Caritha Madiraju. With this funding, in Chris Hollyer's honor, Dr. Madiraju can continue her work at the Sanford-Burnham Medical Research Institute on targeting UBC13-UEV1A for treatment of multiple myeloma.

Like all of our Brian D. Novis Grant winners, research pursuits will lead to improved quality of life for myeloma patients and families everywhere - including Chris Hollyer's listserv friends.



Autumn Tea



Bald-4-Bucks



Glee Club Performance







Car Raffle

Beleficition of Life at Kasbah

Member Fundraisers held between October 1, 2010 – September 30, 2011

BENEFACTORS' CIRCLE \$25,000 AND UP

Miles For Myeloma 5K Philadelphia Multiple Myeloma Networking Group, Central New Jersey Support Group, Northern New Jersey Support Group Philadelphia, PA

A Celebration of Life at Kasbah Allan Weinstein Paradise Valley, AZ

Coach Rob's Benefit Bash Rob Bradford Apopka, FL

Annual Carolyn Czerkies Charity Golf Outing Czerkies Family Naperville, IL

FOUNDERS' CIRCLE

\$10,000 - \$24,999 RHS Open Suzanne Saletan and Family Wellington, FL

Misbehave for Myeloma 2 Alexandra Zousmer and Joanna Share Chicago, IL

J.C. Golf Tournament David Johnson St. Cloud, MN

Pytlik Walk of Hope Barb Pytlik Tonawanda, NY

A Song For Ireland Doug and Kate Farrell Philadelphia, PA

Honoring Peter Pritchett Fundraiser Paul Wiesner Montrose, CO

Matthew Jacobs Annual Fundraiser Matthew Jacobs Frisco, TX

PARTNERS' CIRCLE

\$5,000 - \$9,999 Music Against Myeloma

Slava Rubin New York, NY **Bonacorsi Car Raffle Fundraiser** Mario Bonacorsi

Barre, VT Bald For Bucks David Chan and Steven Brown

Bayside, NY **Pipo's Fund For A Miracle** Cecilia Izquierdo Miami, FL

Passport To A Cure Greg Strouse Brighton, MI

Glee Fundraiser Allison Tuohy Prospect, CT

Paparella Family Fundraiser Carl Paparella St. James, NY

ASSOCIATES' CIRCLE

\$1,000 - \$4,999 Fall Bocce Classic for The IMF Dick Bloom Dayton, OH **Bridge Blasts Myeloma** Ann Girod Potomac, MD

Meredith Fiacco Memorial Golf Tournament Melanie Nicols and Suzanne Fiacco Potsdam, NY

Gary C. Heuer, Jr. Memorial Golf Tournament Nancy Heuer Caledonia, NY

Jack's 6th Annual Texas Hold 'em Benefit Bash Jack Aiello San Jose, CA

Dennis Werra Fundraiser Jayson Werra New Berlin, WI

Trooper Benson Klein Research Fund Benson Klein Bethesda. MD

Margaret R. Cole Memorial Fund Roger Cole Upper Montclair, NJ

Concannon Family Fundraiser Karen Concannon Niantic, CT

Central Florida Support Group Spaghetti Dinner Ken Fabian and Dick Wells Apopka, FL

Multiple Colors for Multiple Myeloma Pam Larsen Honolulu, HI Bello Clambake

Mary Bello Avon Lake, OH Yee Casual Day

Carol Yee North Hollywood, CA

Jeans Day Friday Diplomat Pharmacy – Brenda Hawkes Flint. MI

Leaving the Beach Fundraiser Doug Farrell Philadelphia, PA

Kennedy Backyard BBQ Geri and Bill Kennedy Redwood City, CA

Snook Casual Day Su Snook Long Beach, CA

Bon-Ton Fundraiser Suzanne Fiacco and Melanie Nichols Potsdam, NY

Schaap Fundraisers Cyndi Schaap Lakeview, MI

Margie's Road to Recovery Judy Montgomery Scarborough, ME

Sunday Brunch For A Cure Ivy Prosper St. Catharine's, Ontario, Canada

Aloha Kakou Walk-A-Thon Cyndi Schaap Lakeview, Ml

Marioni Salon Fundraiser Kerri Marioni Newark, DE

Jerry Walton's Veterans Against Myeloma Campaign Jerry Walton Virginia Beach, VA

FRIENDS' CIRCLE \$500- \$999

Bicycle Mojave and Beyond Andrew Sninsky Newport Beach, CA

Volvo Cars Jeans Day Rockleigh, NJ

An Autumn Tea Debra Schuitt Temecula, CA

Alpha Omega Chapter Fundraiser Pam Kirkendoll Temecula. CA

Morgan's Mitzvah Morgan Machado Potomac, MD

Briggs Wedding Fundraiser Kathleen Briggs Comstock Park, MI

Dinkins Fundraiser Paula Dinkins Pasadena, CA

MMA Fight Fundraiser Doug Ehrhardt Arlington, VA

Hoeflinger Wedding Beth Hoeflinger Newtown, PA

Basque San Francisco 5K Julianne Basques Groveland, CA

Monster Mile Fundraiser Josephine Diagonale Delmarva Support Group (full name) Dover, DE

Myeloma Buddies Paula Kilgallon Rainford, St. Helens UK

Who's Your Daddy Rally Lisa Cash Paducah, KY

Jeans and Jewels Gala 2 Lisa Mehalick Gibsonia. PA

Miller Portrait Fundraiser Kathy Miller

Huntington Beach, CA Dancing For A Lourdes Cure Jarmari Garcia

Philadelphia, PA

Hirschorn for Myeloma Steven Hirschhorn Overland Park, KS

Our Friend Dan Fundraiser Dan Odegard St. Paul, MN

Ida's Day Deborah Hadeka Castleton, VT

Kindness for a Cure Denice Bencel Quakertown, PA

Paul Keddell's Veterans Against Myeloma Campaign Paul Keddell

Poquosan, VA

Bob Brunner's Veterans Against Myeloma Campaign Bob Brunner Virginia Beach, VA

DEVELOPMENT


FINANCIAL STATEMENTS


INTERNATIONAL MYELOMA FOUNDATION Statement of Financial Position September 30, 2011

OBLIGATIONS UNDER CAPITAL LEASES, less current portion NET ASSETS Unrestricted	912,598
OBLIGATIONS UNDER CAPITAL LEASES, less current portion	0,000
	3,503
Total Current Liabilities	\$2,691,851
Line of credit	25,000
Current obligations under capital leases	2,668
Deferred and unrestricted educational grants	2,041,578
CURRENT LIABILITIES Accounts payable and accrued expenses	\$622,605
Liabilities and Net Assets	
TOTAL ASSETS	\$3,607,952
Net Property And Equipment	\$655,709
Less accumulated depreciation	(438,652)
	1,094,361
Computer software	928,628
Furniture, fixtures and equipment Computer equipment	127,671
PROPERTY AND EQUIPMENT, at cost	38,062
Total Current Assets	\$2,952,243
Prepaid expenses	330,223
Contributions and other receivables	1,148,507
Cash and cash equivalents	\$1,473,513
CURRENT ASSETS	

For a copy of our complete audited financial statements, please contact the IMF office

INTERNATIONAL MYELOMA FOUNDATION Statement of Activities For the Year Ended September 30, 2011






Change	in l	nrestricted	Net Assets
--------	------	-------------	------------

REVENUES	
Educational grants	\$6,829,672
General contributions	1,298,889
Donated goods and services	175,651
Seminar fees and support group income	79,446
Interest income	9,620
Total Revenues	\$8,393,278
Net Assets Released From Restrictions	
Satisfaction of program restrictions	\$440,932
Total Unrestricted Revenue And Other Support	\$8,834,210
Expenses	
Program expenses	7,829,756
General supporting expenses	483,057
Fundraising expenses	551,452
Total Expenses	\$8,864,265
DECREASE IN UNRESTRICTED NET ASSETS	(30,055)
Changes in Temporarily Restricted Net Assets	
Contributions	220,150
Fundraising event, net of direct benefit to donors of \$365,	,390 220,782
Net assets released from restrictions	(440,932)
Change in Temporarily Restricted Net Assets	_
Decrease in Net Assets	(30,055)
NET ASSETS, September 30, 2010	942,653
NET ASSETS, September 30, 2011	\$912,598

For a copy of our complete audited financial statement, please contact the IMF office

Expense Breakdown



INTERNATIONAL MYELOMA FOUNDATION Statement of Functional Expenses For the Year Ended September 30, 2011

Total Program Expenses	\$7,829,756	
General Supporting Expenses	483,057	
Fundraising Expenses	551,452	
Total Expenses	\$8,864,265	
Breakdown of Expenses by Program		
PROGRAM	TOTAL EXPENSES	
Research	\$1,481,493	
Patient & Family Seminars	924,144	
Education and Awareness	919,708	
International	897,733	
Nurse	856,111	
Support Groups	566,664	
Clinical Meetings	470,986	
Advocacy	416,742	
Myeloma Today	352,967	
Hotline	305,137	
Website	234,678	
Public Relations	188,744	
Information Mailings	172,783	
Myeloma Manager	19,167	
Bank On A Cure®	16,000	
Myeloma Advisor	6,699	
Total Program Expenses	\$7,829,756	

For a copy of our complete audited financial statement, please contact the IMF office

HONOR ROLL

The International Myeloma Foundation gratefully acknowledges the many people and organizations that have made contributions to our various programs and projects during the past year. Without them, the IMF would not be able to continue providing the excellent, high-quality programs and services upon which our members have come to rely. Their generosity allows the IMF to:

- Invest wisely in research programs like the International Myeloma Working Group, that lead to better treatments for patients today while also funding research grants that lead to critical breakthroughs for tomorrow;
- Advocate on behalf of the entire myeloma community to promote legislation to increase the availability and accessibility of all approved drugs;
- Develop and maintain its highly acclaimed website performing daily updates of the most relevant information available and make available 24 hours a day to all those interested in myeloma;
- Support the IMF's network of over 150 support groups through leadership training, educational materials, and assistance in securing guest speakers and teleconferences with the Hotline;
- Maintain the Hotline and ensure that its coordinators are up to date on the latest research and treatment options so that patients, family, and friends always have a place to turn;
- Expand successful programs such as the Regional Community Workshops to reach even more patients and families, while maintaining unwavering support of established and relied-upon programs like the Patient & Family Seminars;
- Continue to produce and regularly update the more than 100 publications that support patients, doctors and nurses in making informed treatment choices.

The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.

The IMF is here for you.

Chairman's Circle

\$100,000 and above Alice and Louis Weiss AMGEN Oncology The Binding Site, Ltd. Celgene Corporation Genzyme Corporation Medtronic, Inc. Merck & Co. Metzger Law Group Millennium: The Takeda Oncology Company Novartis Pharmaceuticals Onyx Pharmaceuticals, Inc. The V & L Marx Foundation

President's Circle

\$50,000 - \$99,999 CBS Corporation Dorothy and John O'Dwyer

Benefactor's Circle

\$25,000 - \$49,999 The Binding Site Group Ltd. Coach Rob's Benefit Bash, Inc. / Kimberly and Robert Bradford Susie Novis and Dr. Brian Durie General Atlantic Corporation Donna and Steve Feig James Manley Philadelphia Multiple Myeloma Networking Group Raymond James & Assoc. / Robert Ebersole

Founder's Circle

\$10,000 - \$24,999 Bristol-Myers Squibb Company Cancer Cure of America Diplomat Specialty Pharmacy Eli Lilly and Company Joele Frank and Laurence Klurfeld Charitable Fund Genentech Inc HBO Inc. Spencer Howard Dr. Robert Hugin J&J / China J.C. Invitational Golf Tournament / Beverly Lundorff John J. McDonnell & Margaret T. O'Brien Foundation Laurie and Andrew Kuzneski Christian F. Ledlev* Joy and Bill McGinnis Alex Meneses and John Simpson Microsoft Community Affairs Marla and Lowell Paxson Pro Ed Communications, Inc. Estate of Paul Rehorst Monica and Philip Rosenthal Sebia, Inc. Iris and Michael Smith Louise Takata Walsh Street Foundation / Henry Belber Phyllis and Allan Weinstein Worldwide Pants Inc.

Partner's Circle

\$5,000 - \$9,999 12650 Riverside Drive Office Building Barre Rotary Club Cephalon, Inc. Clifford and LaVonne Graese Foundation Gail-Ann and Joe Colaruotolo Complete Healthcare Communications. Inc. David Geffen Foundation Carlos J. Carces Eder Estate of Margaret Holdren Cindy and Robert* Feltzin Frank Carl Bragoli Memorial Award Fund, Inc. Cindy and James Gilbert Clare and Seth Green Charlo and Dale Herbrandson Indianapolis Colts, Inc. Janssen-Cilag C.A. Peter Jessup Susan and Michael Katz Carol and Benson Klein Leaf, Barley & Vine LLc Jill Greenwald and Jon Liebman Nancy Neff PeggyAnn P. Hospice Walk Schwab Fund for Charitable Giving Small Army For A Cause Stifel Nicolaus & Company, Inc. T Rowe Price Rose and Sherle Wagner Foundation / Amy Wagner Michael Winkler Zousmer Family Foundation /

Michele and Arnold Zousmer Associate's Circle

\$1,000 - \$4,999 Paige Abadi Kevin and James Abernathy Fred Chrishon Addison Nelleke and Jack Aiello Amazon com Inc Sandra and H.P. Andrews Susan and Frank Armo Telat Ashraf Avnet Sol and Meri Barer Marty Barrett Harry Bartley Natalie and Tom Bell Bench Warmers Inc. Phoebe and Mike Benziger Jessica Blinkoff* Bloom Hergott Diemer/ Ruth and Jake Bloom Lisa and Richard Bloom Richard Boisture Thomas and Marcia Borger Noeline and Henri Boshoff Mitzi and Gerald Bozarth Branch Banking and Trust Company Wendy Breslow L.J. Brewer Carrie Brillstein Ann and Donald A. Brown David and Prudy Brown Nancy and Michael* Bruno Charles Buerk Mari and Ward Bukofsky Robin Green and Mitchell Burgess Colleen and John Busch Capital Group Charitable Foundation / Leigh A. Morris Nilene and Arnold Chase The Chicago Community Foundation Dianna and Hunter Chiles Karen Chopra Louise and Frank Chut Citrin Cooperman & Company, LLP Coalition of Cancer Cooperative Groups Gail and Harold Cohen Karen and Paul Concannon Janice Corwin Marilyn and Lee Cox Barbara and James Coy Beverly* and Jon Cross Timothy Crudo Kathy and Howard Cucher John A. Cutler Craig Czerkies Frances Daley David A. Beckerman Foundation Davis Wright Tremaine LLP Betsy and Paul Dawes Aldo Del Col Design Printing Donna and Mark Di Cicilia Gordon Doble Dr. Armand Dorian Herbert Dornbusch Alice Duffy Debbie and John Dyer Eclipse Band LLC Clarice L. Eder Vince and Mary Jo Elhilow Joseph Daniel Ellis Nil Erdal Estate of Janice Mileo Frances Fahsel Kate and Douglas Farrell Stephanie Hope Feld Jill Freeman Barbara and Buddy Freitag Sid Fry Thomas R. Fuhrman G&S Auto Judie and Howard Ganek Susan and Daniel Gannon Garden State Pharmacy Owners, Inc Stephen Gendel JoAnn Gilbert Michele and Michael Ginsburg Virginia Gloor Nancy and Gary Goodenough Google Matching Gifts Program The Gores Group Susan and Richard Gruasman Sharon Greenwood David Gresens Roslyn and Harold Grueskin Erwin Gudelsky Gursey | Schneider LLP Kathleen Hamburger Anne Hansen Kenneth Harris Judith Hartig-Osanka Landis V. Haugen Helene S. Whitman Memorial Cancer Fund / Joel Whitman Helping Hand Associates Mr. Jason P. Hendler and Mr. Chad Billmyer Michael G. Heuer Winnie Holzman and Paul Dooley Jeffrev Hu Tamara and David Hubler Robert I. Hurley Juli and Herb Hunter IBM Corporation Independent Charities of America Mike Jackson Thomas Jacobson Janssen-Cilag - Panama Janssen-Cilag Kieran Jav

Sara and Rafael Kapustin Arnold Kas Nancy Kelsey Kenneth A. Abrams Charitable Foundation Esther and Bernard Klein Roberta and Raymond Klein Connie and Gary Kluever Kathleen* and Edgar Koschmann Pat Koval KPA Services 110 Kennetha and John Krehbiel Charlene and Dr. Robert Kyle Richard LaGravenese Andrew G. Lebkuecher Tony LeDonne Keith B. Leffler Linda S. Leffler John Lemieux Adrienne Levine Samantha Gerber and Eric Levine Adrienne and Martin Levine Joan and Evan Lewis Lively's Washmobile INC. Katherine and Carl* Locher Kerri and Thomas Mahan Joann K. Malta Flizabeth Manczak Maurice and Carol Feinberg Family Foundation, Inc. Leroy and Delano Burton* May Jamie Duran Mazuera Patty and Fred McClintock Toni and James McCook Rose Linda Meltzer Merck Partnership For Giving Meredith Fiacco Memorial **Golf Tournament** Deborah and Charles F. Metzger Microsoft Giving Campaign MaryAnn Miller Millis, Jenkins, & Hahl Nicole and David Mitchell Linda Molitor Montclair Beach Club, Inc. Judy Montgomery Montrose Memorial Hospital Susan and Richard Moore Diane Moran and Archie Go Morgan Keegan & Company Leigh Morris Mtv Networks Network for Good James Nevik New York Life Giving Campaign New York Life Insurance Company Sharon and Chuck Newman Kevin Nicewonder Carol and Thomas Nicklaus Nuveen Investments John O'Dwyer Margaret and Russell Okasako OverDrive, Inc. Anne M. Pacowta Paradigm Joy and Ronald Paul Allan Pearson Diane and Rick Pedack Sandy and Steve Perlbinder Frances A. Petroziello Pincus Family Foundation / Leslie Pincus Bradford Porter

Nan and Michael Johnson

HONOR ROLL

Premier, Inc S. Vincent Rajkumar, MD Doug Reinhardt Desiree Asher Reynolds Lawrence Revnolds Ariane Ricca Judith and Milton Riseman Rittenberg Family Foundation/ Cindy and Leon Rittenberg, Jr. Sylvana and Matthew Robinson Laurie K. Robinson Robert Rome Janet and Marvin Rosen Sandy and Mark Rothman Marilyn and Gerald Roye Kim and Dr. Marty Rubin SakeOne Kimberly Saletan Suzanne Saletan Salon 92611C The San Francisco Foundation Robert Santos Beverly Sassoon Janice Scanlon* Cyndi and David Schaap Ilona and E. Michael Scott Carrie* and David Powers Sempra Energy Siemens Caring Hands Foundation Cynthia and Igor Sill Anne Marie Silver Mary Anne Siska Keith Small Daphne Smith RuthAnn and Charles Spirakis Virginia Stahlsmith Janet Stanard Michael Stone Talisman Energy, Inc. Dorothy and Hollis* Tinsler Tolleson Management LP Mary and Terry Tomann Truist l inda Van Kessler Paula Van Riper Sue and Harold VanDuyn Dr. David Vesole Karen and Kent Vorhies Barbara and John David Wainwright Mariorie and Joe Walsh Lindsay and Jerry Walton Patricia and Clark Ward Roberta and Marvin Waronoff Rand and Charles Wax Gavle and Evan Weiss Paul Wiesner Kristi and Chick Willette William Morris Endeavor Entertainment lan Williams Sharyne and Mitchel Wolfe David L. York

Friend's Circle

\$500 - \$999 Abbott Laboratories Employee Giving Campaign / Sparna T. Mehta and Donna Wilkinson Mona Abrams Franz A. Adler Aegis Matching Gift Program Pamela Ahlen Lois and Bernard Akin Lee J. Allen Mary Ann and Jeffrey Allyn Alpha Omega Chapter / Theta Chi Epsilon Sorority Linn Anderson Mary and Robert Andriola Aptium Oncology, Inc. Rosemarie Aramanda Carolyn Armington

AT&T Employee Giving Campaign Jennet Walker and John Auerbacher Bae Systems Employee Community Fund, Inc. Baker & Hostetler LLP Lauren and George Baker Madelyn and Kamel Baladi Dusten Balderrama Pauline and Kenneth Barclay Carole and Norman Barham Barnes Group Foundation, Inc. Marion and Henry* Becker Bela B. Nevai & Clara Nevai Charitable Foundation Malea and Michael Bell Mike Bell Marcy Bernstein Jack M. Berry, Jr. Jerome Bess Arin Assero and Steve Bessen Best Western Kodiak Inn Jayne Bianchi Debbie and Jeff Birns Blessed Trinity Parish Blue Shield of California William Blum Vera Bond Maggie and Norman Brokaw Betsy Burgett Susan Cahn and Mario Batali Colleen Campbell-Miller and Philip W Miller Jeff Cao Denise Carmody Jack Carter CDS Property Group David Chan Beatrice Chaney Georgann and Ron Charlton Chevy Chase Michael Chernuchin Monica Chill and Victor Alas Willis G. Clark ClubPokerLeague LLC Valerie and Gary Clucas Garv Cole Kitty and Byron Collier Judith and Neil Collier Ronald Collman Community Foundation of New Jersey Connecticut Multiple Myeloma Fighters Christy Corrigan Corsetti Structural Steel Mary Turner and Kelly Cox Leslie Cutler Mike Daleiden Michael Daley Dallas Support Group Blythe Danner Charisse and John DeFlice Carol and Robert Delsman **Brigitte Demes** Dennis A. Quinn & Associates The Department Beth DeWoody Ann Dieperink . Yvelisse Tejeda Dinte and Paul Dinte Sandra Drant Patti and Peter Dunn **Ben Durie** Annette and Joseph Dutton Joan and Doug Edelen Michael Eisenbrey Barbara and David Elson Employee's Community Fund Of The Boeing Company Spyros Fabrikant Karen and Matthew Falcone Charlotte and Harold Feder Pam and Art Ferrario George Speen

Melissa Fisher William P. Fisher Tom Fontana The Foundation For Jewish Philanthropies Jeanne and Robert Fowler FPC Consulting, LLC David R. Francescani Lana and Paul Franklin Paul Fridell Jan and Don* Froeschle Ursula and Jim Gaines Katherine Garav F.H. Gardner Marilyn and Gerald Gelfand David Girard Len Giuffre Give With Liberty Goldman, Sachs & Co. Matching Gift Program Ronda Gomez-Ouinones Marvin Gottlieb Patricia Gradillas Donna Wyatt and Daryl G. Graham Roberta and Arnold Greenberg Wendy Barish and Michael Greenstein Susan A. Gregory Margaret and Patrick Grippe Virginia F. Gunderson Marc Gurvitz Robert J. Haggerty William J. Handlin Erica Hansen Erica Hanson and Joshua Elbaum Susan Heard Betty and Steve Herman Rose Anne Herrmann Paul Hewitt Sandy Hill and Frank Walsh Gail A. Hills Jennifer and Richard Hogan Hogg, Council on Academic Personnel Terrance M. Hopkins Craig Howard Randall Hughes Elsie Hull HWOA Judith and Mr. Herbert Hyman David Israelson Deanny Jacobson Dominic Jean Margaret and Ralph Jensen Rose and Robert Jernigan Judith Richmon Torrez and William Jewell Jewish Community Foundation Los Angeles Fave Johansen John R. Jakobson Foundation, Inc. / Joan and John Jakobson lanet and Daniel Johnson Kathleen and David Johnson Michael Johnson Doreen and Robert C. Johnson Mary Novak-Johnson and Stuart Johnson Helen* Jordahl Kane Construction Albert V. Kanner Leonard Karasyk Boris Karpman Suzanne and Michael Kay Randy Kelley Mary and William Kenney Lloyd E. Kessler Gloria I Kielev Sara and Joel Kirstein Susan Klein Kenneth Kochmann Beulah Kramer Spencer Krane Stanley E. Krueger Marlene and Richard Kunin Catherine L Kuntz Amy Bard and Stuart Kuritsky

Jamie Larsen Laurie Lasseter Carol Le Rov The Learning Shop Helen and Fay Lee Yow Yuh Leu Nancy and Larry Levitt Kathleen and Charles Lewis Elizabeth and Patrick Lezark Drek Lipp Randi Lundy Mary and Ken Makowka Brian Mann Michael F. Marek Richard Mayo lill McAllister Carol and Robert McCoy Michael McLemore Elizabeth and Bill Mcleod Medco Employee Giving Campaign Nellv Medeiros Nancy and Christopher Meier Lorraine and Joseph Merluzzi Edwin Miller Luvisminda Milo Tom Mingen Natilee* and Kenneth Mintz Edith Mitchell Michael Mobley Ellen Moore Lori Morden Lawrence Moreland John Morrell Kavlene Moss Motorola Foundation Craig and Aline Napoli Nathan Family Foundation Lorraine and Melvine Navone Pamela Nemecek Margaret and Daniel Nencka Joan O'Callaghan Laura Anne O'Donnell Patricia and James Omel Joy Paul Peacock Construction, Inc. Letitia Anne Peplau Karl Pettijohn Ronald Petty Phillippe Family Judith and Philip Phillips Beki Pcus Barbara and Mark Rabin Mary* and Jose Randall Recellular Inc. Michael Reinert Jim and Abigail Rich Brian Rodgers Sara and Richard Rosene Rosenson Family Foundation Harold Rosenson Phillis Rosenthal Rotary Club of York-North John D. Rybarczyk Mary B Schaefer Joan and Zoltan Schelly Jan and Doug* Schmeeckle Frank Schreiner William H. Schubert Diane Seccombe Joanna Share Rosemary and David* Shea The Sherwin-Williams Company Sherwood Inc Gloria Shulman Christine M. Simpson David Sloan Rachel and Michael Small Ursula and William Smeader Marvanne and Charles Smith Martha and Olvis Spencer Karen Jones Squires and James Squires Ronnie and Joe Stabler Diane and Steven Staves Anne Stephens-Aronin Phylis and Richard Stern Taffy J. Stern Dan Stevenson Riza Stillwell Sam Stone Larry E. Stump* Nancy and Jay Style Mindy and Randolph Tammara Jan Tanner Sherrill and Gene Taylor Katharine and David Teitelbaum Soren Thorvald Nancy and William Tidwell Suzie C. Tindall Debbie and Albert Tone Terence Tracey Catherine and W. Roger Trenkle liann D Tsai Virginia and Walter Tulip Robin and Michael Tuohy Rita Ullman Eva Ung United Technologies Matching Gift & Volunteer Grant Programs United Way of Central New Mexico United Way of DEAP Upside Group Franchise Consulting Raymond Uzanas Mary and Raymond Vaillancourt Valley Auto Wreckers Lynn and Franklin Vogel Kathryn F. Waldron Mary and Bob Waldrop Karen and Brian Walls George Ward, Jr. Ryan J. Watts Brian Weber Stuart Weinberg Justin Weiss Wells Fargo Community Support Campaign Rita and Henry Wells Holly and Jayson Werra Dale White Robin and Charles Wilkins Mark Wittcoff Caroline and Herbert Wolf Winthrop Wyman Sandy Zemer Walter Zifkin Judy-Ann Zoghby Alexandra Zousmer

The IMF's 2011 fiscal year ran October 1, 2010 - September 30, 2011. This list includes gifts received between those dates. We apologize for any omissions or errors. Please call the IMF office to report any corrections needed.

Every gift is appreciated by the IMF. Every dollar counts. More than 5,100 people contributed gifts between \$1 and \$499, totaling \$538,225 of support for programs, services, and research. Unfortunately, space does not allow for everyone's name to be listed but every donor is deeply valued.

* deceased

Improving Lives • Finding the Cure





INTERNATIONAL MYELOMA FOUNDATION

12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA 800-452-CURE TheIMF@myeloma.org myeloma.org